This suggested that angiogenesis is associated with the occurrence and development of thymomas (type B2); thus VEGF, VEGFR1 and VEGFR1 maybe the prognostic and prognostic markers for anti‐angiogenesis therapies [6]. This evidence concerns the gene VEGFA and thymoma.